Central Trust Company’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.06M Sell
6,929
-61
-0.9% -$9.35K 0.02% 338
2025
Q4
$964K Sell
6,990
-260
-4% -$34K 0.02% 347
2025
Q3
$930K Sell
7,250
-79
-1% -$9.64K 0.02% 345
2025
Q2
$887K Hold
7,329
0.02% 340
2025
Q1
$817K Buy
7,329
+256
+4% +$27.3K 0.02% 344
2024
Q4
$688K Buy
7,073
+5
+0.1% +$533 0.02% 367
2024
Q3
$813K Sell
7,068
-318
-4% -$36.1K 0.02% 351
2024
Q2
$786K Sell
7,386
-249
-3% -$25K 0.02% 347
2024
Q1
$739K Sell
7,635
-510
-6% -$52.3K 0.02% 364
2023
Q4
$822K Buy
8,145
+70
+0.9% +$6.76K 0.02% 338
2023
Q3
$823K Sell
8,075
-7
-0.1% -$711 0.02% 338
2023
Q2
$816K Buy
8,082
+355
+5% +$35.5K 0.02% 348
2023
Q1
$711K Buy
7,727
+270
+4% +$23.6K 0.02% 352
2022
Q4
$676K Buy
7,457
+76
+1% +$6.4K 0.02% 348
2022
Q3
$561K Sell
7,381
-644
-8% -$53.4K 0.02% 357
2022
Q2
$678K Sell
8,025
-500
-6% -$43.9K 0.02% 338
2022
Q1
$748K Buy
8,525
+136
+2% +$11.8K 0.02% 350
2021
Q4
$734K Sell
8,389
-94
-1% -$7.8K 0.02% 377
2021
Q3
$694K Sell
8,483
-200
-2% -$18K 0.02% 374
2021
Q2
$792K Buy
8,683
+200
+2% +$17.8K 0.03% 344
2021
Q1
$725K Sell
8,483
-1,874
-18% -$168K 0.03% 345
2020
Q4
$978K Sell
10,357
-461
-4% -$40.3K 0.04% 281
2020
Q3
$941K Sell
10,818
-1,904
-15% -$165K 0.04% 257
2020
Q2
$1.11M Sell
12,722
-486
-4% -$42K 0.06% 225
2020
Q1
$1.09M Buy
13,208
+623
+5% +$55.6K 0.07% 211
2019
Q4
$1.19M Buy
12,585
+1,997
+19% +$179K 0.06% 233
2019
Q3
$920K Buy
10,588
+728
+7% +$65.4K 0.05% 256
2019
Q2
$890K Sell
9,860
-831
-8% -$70.3K 0.05% 254
2019
Q1
$921K Buy
10,691
+22
+0.2% +$1.77K 0.05% 241
2018
Q4
$821K Sell
10,669
-301
-3% -$23.4K 0.05% 241
2018
Q3
$847K Sell
10,970
-103
-0.9% -$7.61K 0.05% 259
2018
Q2
$750K Sell
11,073
-3,596
-25% -$248K 0.05% 273
2018
Q1
$1.06M Buy
14,669
+3,587
+32% +$273K 0.07% 235
2017
Q4
$833K Sell
11,082
-951
-8% -$71.8K 0.05% 266
2017
Q3
$926K Buy
12,033
+115
+1% +$8.69K 0.06% 247
2017
Q2
$891K Sell
11,918
-2,514
-17% -$178K 0.06% 254
2017
Q1
$961K Sell
14,432
-126
-0.9% -$8.4K 0.06% 233
2016
Q4
$950K Buy
14,558
+210
+1% +$13.6K 0.07% 233
2016
Q3
$1.02M Buy
14,348
+42
+0.3% +$3.06K 0.07% 214
2016
Q2
$1.06M Buy
14,306
+504
+4% +$34.8K 0.08% 215
2016
Q1
$896K Buy
13,802
+2,956
+27% +$201K 0.07% 223
2015
Q4
$836K Buy
10,846
+179
+2% +$14.2K 0.07% 226
2015
Q3
$879K Sell
10,667
-4
-0% -$356 0.08% 218
2015
Q2
$941K Sell
10,671
-47
-0.4% -$4.31K 0.07% 226
2015
Q1
$947K Sell
10,718
-384
-3% -$34.1K 0.08% 209
2014
Q4
$921K Buy
11,102
+77
+0.7% +$6.38K 0.08% 209
2014
Q3
$930K Sell
11,025
-704
-6% -$57K 0.07% 221
2014
Q2
$952K Sell
11,729
-7
-0.1% -$551 0.08% 216
2014
Q1
$894K Sell
11,736
-802
-6% -$58.4K 0.07% 220
2013
Q4
$903K Sell
12,538
-373
-3% -$25.9K 0.08% 218
2013
Q3
$888K Sell
12,911
-307
-2% -$20.3K 0.08% 207
2013
Q2
$837K Buy
+13,218
New +$860K 0.08% 210

Other funds holding NVS

Central Trust Company's NVS Position: Q1 2026 in Review

Central Trust Company reduced its Novartis (NVS) stake by 0.87% in Q1 2026, selling an estimated $9.35K and leaving 6,929 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #338.

Central Trust Company first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.19M in Q4 2019. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Central Trust Company held 6,929 shares of Novartis worth $1.06M as of Q1 2026.
  • Central Trust Company sold 61 Novartis shares in Q1 2026, an estimated $9.35K.
  • Novartis made up 0.02% of Central Trust Company's portfolio in Q1 2026, its #338 holding.
  • Central Trust Company first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Central Trust Company's Novartis position peaked at $1.19M in Q4 2019.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.